Compounding Chemotherapy Market Size, Share, Growth, Trends, and Global Industry Analysis: By Dose Type (Chemotherapeutic, Non-Chemotherapeutics, Others), By Compounding Type (Pharmaceutical Ingredient Alteration (PIA), Currently Unavailable Pharmaceutical Manufacturing (CUPM), Pharmaceutical Dosage Alteration (PDA), By Delivery Method (Gravimetric Automated Compounding Device (weight-based), Volumetric Automated Compounding Device (volume-based)), By Sterility (Sterile, Non-sterile), By Technology (With Robotic Arms, Without Robotic Arms), and Region Forecast 2020-2031

Compounding Chemotherapy Market size was valued at US$ 1,420 million in 2024 and is expected to reach US$ 2,080 million by 2031, growing at a significant CAGR of 5.6% from 2025-2031. Moreover, the U.S. Compounding Chemotherapy Market is projected to grow significantly, reaching an estimated value of US$ 710 million by 2031. The market is evolving in response to growing oncology cases and the need for personalized medication solutions. Compounding chemotherapy involves preparing customized cancer drugs to meet specific patient requirements in terms of dosage, formulation, or combination. Hospitals, cancer treatment centers, and specialty pharmacies rely on sterile compounding to ensure accurate and safe drug preparation, especially for patients who cannot tolerate standard formulations.

The increasing prevalence of cancer, combined with the limitations of one-size-fits-all chemotherapy protocols, has fueled demand for compounded chemotherapy. Moreover, compounding supports dose optimization, reducing side effects and improving therapeutic outcomes, which has become a priority in patient-centric oncology care. Stringent quality control, specialized infrastructure, and trained professionals are key to compounding practices, making it a highly regulated segment. As cancer care becomes more sophisticated, oncologists and pharmacists are turning to compounding solutions for tailored regimens, especially for pediatric, geriatric, and immunocompromised patients.

Additionally, the integration of automated compounding systems enhances accuracy, minimizes contamination risk, and aligns with evolving safety protocols. With cancer treatment becoming more targeted and combination-driven, compounded chemotherapy will play a vital role in delivering personalized, precision-based care. The market is thus gaining prominence as an indispensable element of next-generation oncology services.

Facts & Figures

• Automated gravimetric compounding systems are preferred in large oncology centers for accuracy and sterility assurance.
• Pharmaceutical Ingredient Alteration is a leading compounding type used when standard formulations cause intolerances.
• Sterile compounding dominates the market due to strict safety standards in injectable chemotherapy preparation.
• Robotic arms in compounding setups are becoming essential in reducing occupational exposure and boosting output.

Key Developments:

• InMay 2025, Baxter International launched a closed-system automated compounding device for chemotherapy in North America.
• In April 2025, Grifols partnered with hospital networks in Europe to expand centralized oncology compounding services.
• In February 2025, CAPS opened a new sterile compounding facility in Texas, boosting regional oncology support.
• In January 2025, Braun expanded its automated compounding service footprint into Asian oncology centers

Compounding Chemotherapy Market Segmentation:

Based on the dose type:

• Chemotherapeutics
• Non-Chemotherapeutic
• Others

Chemotherapeutic compounds dominate the global market, as most compounded formulations are tailored versions of existing oncology drugs. These include dose-adjusted cytotoxic agents or customized combinations for specific cancer types. Oncologists prefer such compounding to improve patient tolerance, especially during aggressive multi-line treatment. Demand for compounded chemotherapeutics is high in pediatric and rare cancer cases, where standard commercial dosages may not apply. Hospitals and specialty pharmacies utilize sterile environments to prepare these personalized treatments. The segment's importance is further heightened by clinical reliance on drug reformulations during supply shortages or adverse reaction cases, ensuring uninterrupted care. As oncology care personalizes, chemotherapeutic compounding remains foundational.

Based on the compounding type:

• Pharmaceutical Ingredients Alteration (PIA)
• Currently Unavailable Pharmaceutical Manufacturing (CUPM)
• Pharmaceutical Dosage Alteration (PDA)

Pharmaceutical Ingredient Alteration is a key compounding type in oncology where allergens, excipients, or drug strengths are adjusted based on patient tolerability. This is especially useful for patients with hypersensitivity to preservatives or fillers found in commercial chemotherapy products. The process demands precise pharmaceutical knowledge and sterile protocols, ensuring altered formulations remain stable and effective. Oncology settings rely heavily on this compounding type to avoid adverse reactions and provide consistent therapeutic results. Its adaptability makes it ideal for pediatric oncology, where traditional formulations may not suit developmental needs. As awareness grows, this segment continues to gain favor in personalized chemotherapy solutions.

Based on the delivery method:

• Gravimetric Automated Compounding Device (Weight based)
• Volumetric Automated Device (Volume based)

Gravimetric compounding devices, which calculate dose by weight, are widely adopted for their accuracy and traceability. These systems are preferred over volumetric models for their ability to deliver consistent, contamination-free results in chemotherapy drug preparation. Oncology centers favor gravimetric devices due to their compliance with sterility standards and minimal human intervention. The integration with safety cabinets and barcode validation ensures high reproducibility. As precision and accountability in drug delivery become critical in chemotherapy, gravimetric systems are gaining widespread use across developed healthcare settings. The ability to interface with digital health records also enhances traceability and reduces dosage discrepancies.

Based on the Sterility:

• Sterile
• Non-Sterile

Sterile compounding forms the backbone of chemotherapy preparation, as these drugs are administered intravenously and must be free of microbial contamination. Sterile practices are governed by global standards like USP <797>, necessitating controlled environments, laminar flow hoods, and rigorous technician training. Hospitals and outsourcing facilities maintain ISO-certified cleanrooms to meet these requirements. The sterile segment leads due to its essential role in patient safety and therapeutic reliability. As oncology drug protocols become increasingly complex, the demand for sterile, precise, and timely compounding rises. This segment continues to attract investment for infrastructure upgrades, automated solutions, and skilled workforce development.

Based on the technology:

• With Robotic Arm
• Without Robotic Arm

Robotic arms are revolutionizing the compounding chemotherapy process by improving accuracy, consistency, and safety. These systems minimize human exposure to hazardous drugs and reduce manual errors associated with repetitive handling tasks. Equipped with AI algorithms and barcode scanning, robotic arms ensure proper drug selection, dose verification, and documentation. They are increasingly deployed in centralized compounding labs and high-volume cancer hospitals. The technology is vital for maintaining aseptic conditions and improving throughput during high-demand cycles. As healthcare systems seek automation for safety and efficiency, robotic arms are becoming a preferred investment for institutions offering advanced oncology services.